CKLIFE SCIENCES(00775)

0.550-0.010-1.79%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- CK Life Sciences to Swing to Loss in 2024
  MT Newswires Live · 03-07
  CK Life Sciences to Swing to Loss in 2024
- BRIEF-CK Life Sciences Intl Sees Loss Attributable Of HK$126.6 Million For Year
  Reuters · 03-06
  BRIEF-CK Life Sciences Intl Sees Loss Attributable Of HK$126.6 Million For Year
- CK Life Sciences Intl Sees Loss Attributable of HK$126.6 Mln for Year
  THOMSON REUTERS · 03-06
  CK Life Sciences Intl Sees Loss Attributable of HK$126.6 Mln for Year
- CK Life Sciences Intl - Expected Result Due to Decision to Increase R&D Investments & Decline in Fair Value of Vineyard Portfolio
  THOMSON REUTERS · 03-06
  CK Life Sciences Intl - Expected Result Due to Decision to Increase R&D Investments & Decline in Fair Value of Vineyard Portfolio
- CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) Surges 27% Yet Its Low P/S Is No Reason For Excitement
  Simply Wall St. · 01-28
  CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) Surges 27% Yet Its Low P/S Is No Reason For Excitement
- Market Chatter: CK Asset, CK Hutchinson to Invest in Carbon Sequestration in Australia
  MT Newswires Live · 2024-11-01
  Market Chatter: CK Asset, CK Hutchinson to Invest in Carbon Sequestration in Australia
- CK Life Sciences Sells Stake in Pharmagesic to Nasdaq-Listed Virios for $100 Million; Shares Rise 8%
  MT Newswires Live · 2024-10-08
  CK Life Sciences Sells Stake in Pharmagesic to Nasdaq-Listed Virios for $100 Million; Shares Rise 8%
- BRIEF-CK Life Sciences Intl Says Unit To Sell Pharmagesic (Holdings)
  Reuters · 2024-10-07
  BRIEF-CK Life Sciences Intl Says Unit To Sell Pharmagesic (Holdings)
- CK Life Sciences Intl - Unit to Sell 100% Stake of Pharmagesic (Holdings) for US$100 Mln
  THOMSON REUTERS · 2024-10-07
  CK Life Sciences Intl - Unit to Sell 100% Stake of Pharmagesic (Holdings) for US$100 Mln
- CK Life Sciences Int'l. Appoints CEO
  MT Newswires Live · 2024-09-20
  CK Life Sciences Int'l. Appoints CEO
- CK Life Sciences Intl - Lance Richard Lee Yuen Appointed as Executive Director, Vice President and CEO
  THOMSON REUTERS · 2024-09-20
  CK Life Sciences Intl - Lance Richard Lee Yuen Appointed as Executive Director, Vice President and CEO
- CK Life Sciences Intl - Yu Ying Choi, Alan Abel Re-Designated From Vice President and Chief Executive Officer to Deputy Chairman
  THOMSON REUTERS · 2024-09-20
  CK Life Sciences Intl - Yu Ying Choi, Alan Abel Re-Designated From Vice President and Chief Executive Officer to Deputy Chairman
Company Profile
Company Name
CKLIFE SCIENCES
Market
SEHK
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.ck-lifesciences.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
CK Life Sciences Int'I., (Holdings) Inc. is a Hong Kong-based investment holding company principally engaged in the development and sales of healthcare products. The Company operates through three segments. The Health segment is engaged in the development, production, marketing and sales of healthcare and pharmaceutical products. The healthcare brands under the Company include Lipa, Vitaquest and Sante Naturelle, among others. Its pharmaceutical products include cancer-related pharmaceuticals and painkillers, among others. The Agriculture-related Businesses segment is engaged in the operation of vineyards, as well as the development, production, marketing and sales of agriculture and related products. Its agricultural products include fertilizers and crop protection products, among others. The Investment segment is engaged in the investment in financial and investment products.

1D
5D
Day
Week
Month

High

0.560

Open

0.550

Volume%

1.11

Low

0.540

0.560

T/O Rate

0.10%

抱歉，当前请求异常(-1)

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

To The Moon

CKLIFE SCIENCES(00775)

CKLIFE SCIENCES(00775) 2022Q4 Earnings Summary

Company Profile